This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results- 3Liver transplantation
- 1Children
- 1Epigallocatechin gallate
- 1Hepatitis C infection
- 1Hepatitis C virus
- 1Immunotherapy
-
Development of an ex vivo assay of hepatitis C specific T-cell responses using QuantiFERON®
DownloadSpring 2011
Cellular immune responses to Hepatitis C (HCV) epitopes are crucial for successful host response to HCV infection. We investigated a platform to assess specific and global immune responses in HCV infection. We identified 57 HCV peptides from literature (24 of CD4+, 33 of CD8+ specificity) and...
-
Novel Agents Inhibiting Hepatitis C Virus; Application to Prevention of Re-infection after Liver Transplantation
DownloadFall 2013
Recurrent Hepatitis C virus infection drives inferior outcomes experienced by patients undergoing liver transplantation due to HCV-associated liver disease. Existing therapies exhibit increased toxicity, poor efficacy, and profound patient intolerability in the immediate transplantation period....
-
Sarcopenia is associated with clinical outcomes and physical function in children with end-stage liver disease pre-and-post liver transplantation
DownloadSpring 2020
Background & Aims: Sarcopenia is defined as reduced skeletal muscle mass (myopenia), muscle strength and physical performance. In adults with end stage liver disease (ESLD), sarcopenia is highly prevalent and associated with adverse outcomes. Emerging data have shown that sarcopenia is prevalent...